Degarelix Research

Bartlewski J, Oliveira MEF, Bartlewski PM

Sixteen multiparous Santa Inês ewes underwent transrectal ovarian ultrasonography from days 6 to 17 (D6-17; D0 = ovulation). On D6, ewes received a single subcutaneous injection of Firmagon® at a low dose (LD; n = 5; 215 µg/kg body weight [b.w.]) or a high dose (HD; n = 6; 235 &#xb...

Tran B, Yeh N, Gayle A, Holmes E, Hu J, Damineni S et al.

An understanding of how androgen deprivation therapy (ADT) prescribing patterns impact patient outcomes in a real-world setting is needed to help inform treatment decisions and improve the care of patients with prostate cancer (PCa). REASSURE was a retrospective, observational study that describe...

Sasaki A, Yamaba T, Kimura R

In patients presenting with bone lesions suggestive of metastatic prostate cancer, rapid acquisition of diagnostic tissue is essential. Although transrectal ultrasound-guided (TRUS) or transperineal biopsy is standard, these approaches may be impractical in certain clinical settings. Markedly ele...

Kubota H, Kijima T, Matsuda H, Uematsu T, Takei K, Yashi M et al.

Neuroendocrine prostate cancer (NEPC) is often considered treatment-induced. We report a case with pre-existing neuroendocrine differentiation that became evident during androgen receptor signaling inhibitor (ARSI) therapy. A 79-year-old man with metastatic prostate cancer received degarelix plus...

Zhao M, Wei R, Lu Y, Zhu T, Liao Y, Hu W et al.

Degarelix is a long-acting gonadotropin-releasing hormone (GnRH) antagonist that suppresses gonadotropin and sex steroid secretion via competitive blockade of the GnRH receptor (GnRHR). Although its systemic endocrine effects have been clearly identified, its direct effects on non-pituitary-deriv...

Verlinden L, Blanco SC, Liekens T, Stockmans I, Moermans K, Schollaert D et al.

Transgender individuals are increasingly seeking gender-affirming therapy. For children and adolescents, this typically involves puberty suppression followed by hormone treatment. However, potential long-term adverse effects on the growing skeleton remain poorly characterized, largely due to the ...

Giesen A, Devos G, Tosco L, Goffin K, Ahmadi Bidakhvidi N, Laenen A et al.

High-risk prostate cancer (PCa) carries a substantial risk of recurrence and progression after radical prostatectomy (RP). The ARNEO trial previously showed that apalutamide (APA) plus degarelix (DEG) improved the rates of minimal residual disease (MRD) and organ-confined pathology (ypT2) compare...

Machado M, Mourato M, Negrão C, Rodrigues C, Serra JT

Tumor lysis syndrome (TLS) is a life-threatening oncological emergency resulting from massive cellular destruction. Although most frequently associated with chemotherapy in hematologic malignancies, TLS is uncommon in solid tumors due to their typically slower proliferation rates and treatment re...

Chen CJ, Lin HJ

Current versatile treatments for acute vessel occlusion - whether arterial or venous - have significantly improved the success of recanalization. However, patients who present with unexplained thromboembolic events, including arterial and venous, especially in the absence of traditional risk fact...

Penchala Reddy N, Deerush Kannan S, Thirumalai Ganesan G, Pramod Kumar KP, Ragavan N

Prostate cancer is prevalent among men, and Androgen Deprivation Therapy (ADT) remains a cornerstone in managing advanced stages of this disease. However, ADT has been associated with cardiovascular side effects, raising concerns, especially in populations with a high baseline risk for cardiovasc...

Higgi A, Melvin C, Abdelrasheed A, Wilson K

Relugolix is a novel orally administered gonadotropin-releasing hormone (GnRH) antagonist approved for androgen deprivation therapy (ADT) in advanced prostate cancer. Its oral formulation, rapid onset of action, and potentially improved cardiovascular safety profile distinguish it from traditiona...

Liu S, Yu Y, Zhou J, Yang L, Yan X, Liu X et al.

Tertiary lymphoid structures (TLSs) are linked to better outcomes in prostate cancer. Neoadjuvant hormone therapy enhances TLS formation, immune cell infiltration, and tumor response-supporting the potential of combining hormone and immunotherapy for improved treatment.This study investigates the...

Kyriazis I, Bellos T, Katsimperis S, Angelopoulos P, Neofytoy P, Varkarakis I et al.

Androgen deprivation therapy (ADT) is a cornerstone treatment for advanced prostate cancer. While effective, traditional injectable luteinizing hormone-releasing hormone (LHRH) agonists are associated with an initial testosterone flare and potential cardiovascular risks. Relugolix is a novel, ora...

Ahmadi Bidakhvidi N, Giesen A, Devos G, Laenen A, Baldewijns M, Koole M et al.

To investigate the relationship between [18F]PSMA-1007 PET parameters and biochemical recurrence-free survival (BCR-FS) in high-risk primary prostate cancer patients receiving neoadjuvant hormonal treatment.This prospective randomized, double-blind, placebo-controlled phase II trial included 89 h...

Chai Y, Yao Z, Zhou Z, Zhang Y

This meta-analysis compared the efficacy and safety of degarelix and GnRH agonists in prostate cancer treatment.A comprehensive literature search was carried out using PubMed, Web of Science, Cochrane Library, and Scopus. RevMan 5.3 software was applied to conduct the meta-analysis.Degarelix resu...

Agrawal R, Weiner AB, Livingstone J, Pooli A, Huang RR, Ye H et al.

It is thought that androgen deprivation therapy (ADT) resistance and subsequent prostate cancer progression via epithelial-mesenchymal transition (EMT) is induced by the SRC and MEK pathways. We hypothesized that inhibition of these pathways could reduce EMT.In this phase 2 trial, 45 patients und...

Zilli T, Böhmer D, Roeder A, Lauffer D, Villafranca Iturre AE, Jové-Teixidó JJ et al.

External beam radiotherapy (EBRT) combined with long-term androgen deprivation therapy (ADT) is standard for high-risk prostate cancer. EORTC 1414 compared ADT with a luteinizing hormone-releasing hormone (LHRH) antagonist (degarelix) or an LHRH agonist in patients who received EBRT.Between 2017 ...

Liu W, Liu Z, Song L, Zhu H, Luo Y, Zhang J et al.

Regarding the comparison of cardiovascular disease risk between gonadotropin-releasing hormone (GnRH) antagonists and GnRH agonists, there are discrepancies in results from different studies. Therefore, this meta-analysis was conducted to investigate whether degarelix could reduce cardiovascular ...

Valenza C, Etessami JD, Munzone E, Pravettoni G, Curigliano G, Trapani D et al.

To review the current evidence and inform clinical guidance on the implications of incomplete ovarian function suppression (OFS), the utility of serum estradiol (E2) monitoring, and appropriate management strategies in premenopausal women with early breast cancer (eBC) receiving adjuvant luteiniz...

Reijnders E, Bossuyt PM, Jukema JW, Ruhaak LR, Romijn FPHTM, Szarek M et al.

Residual cardiovascular risk remains, despite achieving low-density lipoprotein cholesterol targets with high-intensity statins. Traditional risk scores are suboptimal. This study evaluated the prognostic utility of a 9-plex apolipoprotein panel in recent patients with acute coronary syndrome on ...